Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Cash flows from operating activities:
Net income (loss)	$ 1,731	$ 8,792	$ 11,832	$ 12,080
Adjustments for noncash items:
Depreciation			10,018	12,357
Amortization of identifiable intangibles			879	948
Reduction of right-of-use lease asset			1,064	1,178
Deferred income taxes			1,209	2,248
Accrued pension and post-retirement benefits			107	109
Stock-based compensation expense			919	1,086
Gain on investment in kaléo			0	(144)
Gain on the sale of assets			(1,492)	0
Gain on the sale of divested business	0	0	(9,657)	0	$ 74,900
Changes in assets and liabilities:
Accounts and other receivables			(14,016)	(17,160)
Inventories			(15,263)	(10,357)
Income taxes recoverable/payable			(349)	(539)
Prepaid expenses and other			8,897	2,597
Accounts payable and accrued expenses			2,336	3,305
Lease liability			(1,240)	(1,408)
Pension and postretirement benefit plan contributions			(291)	(306)
Other, net			2,195	1,335
Net cash provided by (used in) operating activities			(2,852)	7,329
Cash flows from investing activities:
Capital expenditures			(5,638)	(4,782)
Proceeds from the sale of Terphane			9,835	0
Proceeds on sale of investment in kaléo			0	144
Proceeds from the sale of assets			1,904	83
Net cash provided by (used in) investing activities			6,101	(4,555)
Cash flows from financing activities:
Borrowings			88,197	340,818
Debt principal payments			(87,494)	(345,140)
Debt financing costs			(1,272)	(587)
Net cash provided by (used in) financing activities			(569)	(4,909)
Effect of exchange rate changes on cash			53	(2,651)
Increase (decrease) in cash and cash equivalents			2,733	(4,786)
Cash and cash equivalents at beginning of period			7,062	13,455	13,455
Cash and cash equivalents at end of period	$ 9,795	$ 8,669	$ 9,795	$ 8,669	$ 7,062